Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants
June 08, 2020 20:48 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Announces Proposed Public Offering of Common Stock
June 08, 2020 06:00 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Provides Data Update from MISSION Study of KZR-616
June 03, 2020 16:02 ET
|
Kezar Life Sciences, Inc.
Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuriaKZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity...
Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference
May 28, 2020 16:01 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to...
Kezar Announces Presentations During Upcoming Scientific Conferences
May 20, 2020 16:41 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
May 07, 2020 16:01 ET
|
Kezar Life Sciences, Inc.
Noreen R. Henig, MD appointed as Chief Medical OfficerAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020IND submission for KZR-261, a...
Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer
May 04, 2020 16:01 ET
|
Kezar Life Sciences, Inc.
SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat...
Kezar Provides Statement Regarding COVID-19 Pandemic
April 09, 2020 07:00 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
March 12, 2020 16:01 ET
|
Kezar Life Sciences, Inc.
Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressingAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences...
Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference
February 26, 2020 16:01 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...